Get under-the-radar study along with StreetInsider.com’s Stealth Growth Insider FREE, along with no bank credit card required for the very first numerous months of publication. Join here.
vTv Therapeutics Inc. (Nasdaq: VTVT) announced that outcomes from an earlier pilot medical study of TTP399, its liver-selective glucokinase activator (GKA) product candidate for the procedure of Form 2 diabetes, were presented at the American Diabetes Association 76th Scientific Sessions.
In a poster presentation titled, “TTP399, a Novel, Liver Selective Glucokinase Activator: outcomes from a 10 Day Pilot Study in Patients along with Form 2 Diabetes Mellitus (T2DM) Naïve to Drug,” researchers from vTv reviewed outcomes showing that TTP399, currently being evaluated in the Phase 2b AGATA study, improved glycemic manage and insulin resistance in treatment-naïve diabetes patients. Importantly, TTP399 did not induce hypoglycemia or have actually harmful effects about plasma lipids, as seen along with previous GKAs that do not target the liver.
“These outcomes include to the physique of preclinical and medical proof that sustain the potential of TTP399 for the procedure of diabetes,” commented Dr. Carmen Valcarce, SVP and Chief Scientific Officer of vTv Therapeutics. “Dual-acting GK activators produced by others caused higher paces of hypoglycemia and hyperlipidemia. We believe TTP399’s liver selectivity and preservation of the physiological regulation of GK—a special attribute of our GKA—mitigates these adverse effects, making this compound potentially helpful very early in the ailment in prediabetes or to intensify treatment free of threat of hypoglycemia. We chance to confirm the efficacy and security of this method and to demonstrate the durability of the effect in our ongoing Phase 2b AGATA study, and anticipate to report topline data in mid-2016.”
The study, section of the TTP399 medical improvement plan, reported data collected from 3 doses of TTP399 compared to placebo in treatment-naïve, mild Form 2 diabetes patients (A1c ≤ 7%) over a 10-day procedure time period (16 patients received 50 mg, 200 mg or 400 mg oral doses of TTP399, 6 received placebo). outcomes showed statistically substantial improvements over placebo in insulin and sugar measures in patients receiving the 2 better doses of TTP399, while reporting comparable edge events as those receiving placebo. No hypoglycemia or harmful effects about plasma lipids were seen in any type of of the TTP399-treated patients.
The Firm expects to report topline outcomes in mid-2016 from the AGATA study, a 180-patient, Phase 2b randomized, placebo controlled, six-month duration study of TTP399 in Form 2 diabetes patients.
A copy of the presentation will certainly be gained readily available in the News & Events section of the Company’s website adhering to the presentation.
